enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Janus kinase inhibitor - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase_inhibitor

    A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

  3. Janus kinase 3 inhibitor - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase_3_inhibitor

    Janus kinase 3 inhibitors work by inhibiting the action of the enzyme Janus kinase 3, thereby interfering with the JAK-STAT signaling pathway.JAK3 is required for signaling by cytokines through the common γ chain of the interleukin receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. [4]

  4. Janus kinase - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase

    Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.They were initially named "just another kinase" 1 and 2 (since they were just two of many discoveries in a PCR-based screen of kinases), [1] but were ultimately published as "Janus kinase".

  5. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib is a Janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. [21] [22] Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression. [6]

  6. Can JAK Inhibitors Challenge Biologics?

    www.aol.com/news/2013-02-20-can-jak-inhibitors...

    The most promising JAK inhibitor in development is Baricitinib from Eli Lilly , which had a strong showing in a phase 2b study for rheumatoid arthritis late last year. However, it will likely be ...

  7. Tofacitinib - Wikipedia

    en.wikipedia.org/wiki/Tofacitinib

    [8] [9] [10] It is a janus kinase (JAK) inhibitor, [8] [9] discovered and developed by the National Institutes of Health and Pfizer. Common side effects include diarrhea, headache, and high blood pressure. [10] Serious side effects may include infections, cancer, and pulmonary embolism.

  8. AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

    www.aol.com/news/abbvies-jak-inhibitor-rinvoq...

    AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

  9. Can JAK Inhibitors Challenge Biologics?

    www.aol.com/2013/02/20/can-jak-inhibitors...

    When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins. It makes sense to use these ...